Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-67484703 in Active Rheumatoid Arthritis
NCT04985812Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing JNJ-67484703 with Placebo (2 arms). Primary endpoints: Percentage of Participants with Treatment-emergent Adverse Events at 24 weeks, Percentage of Participants with Treatment-emergent Serious Adverse Events at 24 weeks and 2 more. Started Oct 2021; status: completed.
02
Drugs
JNJ-67484703
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04985812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985812.